Evaluation of crystal violet decolorization assay for minimal inhibitory concentration detection of primary antituberculosis drugs against Mycobacterium tuberculosis isolates

In this study we evaluated the crystal violet decolorization assay (CVDA) for detection of minimum inhibitory concentration (MIC) of antituberculosis drugs. 53 isolates were tested in this study and 13 of them were multidrug resistant (MDR) isolates. The antibiotics concentrations were 2-0.06 mg/L for isoniazid (INH) and rifampicin (RIF) and were 16-0.25 mg/L for streptomycin (STM) and ethambutol (EMB). Crystal violet (CV-25 mg/L) was added into the microwells on the seventh day of incubation and incubation was continued until decolorization. Decolorization of CV was the predictor of bacterial growth. Overall agreements for four drugs were detected as 98.1%, and the average time was detected as 9.5 ± 0.89 day after inoculation. One isolate for INH and two isolates for STM were determined resistant in the reference method, but susceptible by the CVDA. One isolate was susceptible to EMB by the reference method, but resistant by the CVDA. All results were concordant for RIF. This study shows that CVDA is a rapid, reliable and suitable for determination of MIC values of Mycobacterium tuberculosis. And it can be used easily especially in countries with limited-sources.

Infecções do trato urinário (ITU) de cães e gatos: etiologia e resistência aos antimicrobianos / Urinary tract infection (UTI) in dogs and cats: etiology and antimicrobial resistance

As infecções bacterianas do trato urinário (ITUs) são causa comum de doença em cães, gatos e humanos. Embora bactérias Gram positivas como Staphylococcus spp., Streptococcus spp. e Enterococcus spp., possam ocasionar ITUs, as bactérias Gram negativas (Escherichia coli, Proteus spp., Klebsiella spp., Pseudomonas spp. e Enterobacter spp.) respondem por 75% dos casos. Este estudo teve como objetivo determinar a frequência de diferentes gêneros de bactérias em ITUs em cães e gatos, bem como a sua sensibilidade aos antimicrobianos utilizados na rotina clínica. Portanto, amostras de urina de 100 cães e gatos com sinais de ITU foram coletadas assepticamente, sofrendo avaliação microbiológica por meio de métodos qualitativos e quantitativos, além de urinálise. Todos os isolados foram submetidos a testes de sensibilidade aos antimicrobianos. ITU foi confirmada em 74% dos animais, não havendo predominância quanto ao sexo. No que diz respeito à idade, 85% dos cães e 87% dos gatos tinham idades superiores a seis anos. Noventa e cinco cepas bacterianas foram isoladas, com maior frequência de Escherichia coli (55% do total) dos sorogrupos O6 e O2. Constatou-se níveis elevados de resistência a antimicrobianos nas cepas isoladas. Para as cepas Gram positivas, tetraciclina (46,1%), enrofloxacina, cotrimazol e estreptomicina (42,3% cada) foram as drogas com os maiores índices de resistência. Para as Gram negativas, amoxacilina e tetraciclina apresentaram percentuais acima de 50%. Multiresistência foi verificada em mais de 50% dos principais gêneros isolados. Considerando-se que as cepas de E. coli apresentam potencial zoonótico e forte participação na disseminação de resistência aos antimicrobianos, ressalta-se a importância do papel do médico veterinário na prevenção e controle das ITUs animais e sua contribuição para a saúde pública.

Bacterial urinary tract infections (UTIs) are a common cause of disease in dogs, cats and humans. Although Gram-positive bacteria such as Staphylococcus spp., Streptococcus spp. and Enterococcus spp. are linked with UTIs, Gram-negative bacteria (Escherichia coli, Proteus spp., Klebsiella spp., Pseudomonas spp. and Enterobacter spp.) account for 75% of the cases. This study aimed to determine the frequency of different genera of bacteria in UTIs of dogs and cats as well as their susceptibility to antimicrobials used in clinical routine. Therefore, urine samples from 100 dogs and cats suspected of UTI were collected aseptically. Samples underwent to microbiological evaluation through qualitative and quantitative methods, and urinalysis. All isolates were tested for antimicrobial susceptibility. UTI was confirmed in 74% of animals, with no predominance in one gender. With regard to age, 85% of dogs and 87% of cats were older than six years. Ninety-five bacterial strains were isolated with higher frequency of Escherichia coli (55% of total) of serogroups O6 and O2. High levels of antimicrobial resistance were found. Gram-positive strains had the highest resistance to tetracycline (46.1%), enrofloxacin, cotrimazol and streptomycin (42.3% each), while above 50% of Gram-negative were resistant to amoxicillin and tetracycline. Multidrug resistance has been observed in more than 50% of the major genera isolated. Considering the zoonotic potential of E. coli strains and its strong participation in antimicrobial resistance dissemination, the important role of the veterinarians in the prevention and control of animal UTIs and their contribution to public health must be emphasized.

Tratamiento directamente observado de la tuberculosis en un hospital de la Ciudad de Buenos Aires / Directly observed treatment for tuberculosis in a Buenos Aires City hospital

Se describe la experiencia en la aplicación del tratamiento directamente observado de tuberculosis (TDO) en el período 1/1/1979-31/12/2009 y la comparación de los resultados obtenidos en el periodo 1979-1999 versus los de 2000- 2009. En un hospital de la Ciudad de Buenos Aires, 582 pacientes HIV negativos recibieron inicialmente rifampicina, isoniazida, pirazinamida y etambutol o estreptomicina. En la segunda fase 424 de estos pacientes tratados entre 01/01/1979 y 31/12/1999 (G1), recibieron esquemas bisemanales con rifampicina/isoniazida o isoniazida/estreptomicina y otros 158 pacientes, tratados entre 01/01/2000 y 31/12/2009 (G2) recibieron un esquema bisemanal o trisemanal con rifampicina/isoniazida. Se siguieron las recomendaciones de los programas de control de la Nación y la Ciudad. Los pacientes bajo TDO tuvieron tasas de tratamiento completo más elevadas (82.8% versus 48.7%), (p < 0.0001) con respecto a otros 483, que siguieron tratamiento autoadministrado (AUTO); la edad promedio fue de 36.3 ± 15.3 años, 63.1% eran varones y 69.4% tenían nacionalidad argentina. Presentaron tratamiento previo el 8.9%, comorbilidades el 6.1% y el 70.6% de las formas pulmonares fueron confirmadas bacteriológicamente. El 9.5% presentó efectos adversos a drogas y el sexo masculino presentó mayor frecuencia de abandonos (p = 0.004). Con respecto al G1, en el G2 hubo menor proporción de pacientes argentinos (48.7% vs. 77.1%), (p ≤ 0.0001), mayor frecuencia de comorbilidades (10.7% vs. 4.4%), (p = 0.005), de formas clínicas pulmonares con confirmación bacteriológica (95% vs. 87%), (p = 0.02) y de efectos adversos a drogas (17% vs. 6.6%), (p ≤ 0.0001). Hallamos tasas de cumplimiento total elevadas en TDO (82.8%), similares a las otras publicaciones.

The outcomes of directly observed therapy of tuberculosis (DOT) between 1/1/1979 and 12/31/2009 were analyzed. Results obtained in the 1979-1999 period were compared with those achieved in the 2000-2009 period. In a Buenos Aires City hospital, 582 HIV negative TB patients received rifampin, isoniazid, pyrazinamide and ethambutol or streptomycin in the initial stage, followed by a second stage where patients were included in two groups: G1 composed by 424 patients (period 1/1/1979-12/31/1999) who received either rifampin and isoniazid or rifampin and streptomicin twice a week, and G2, with 158 patients (period 1/1/2000-12/31/2009) who received either rifampin and isoniazid twice or three times a week. National and Buenos Aires City TB Control Programs recommendations were followed. Patients who underwent DOT had higher completeness rates than those included in self-administered therapy (82.8% vs. 48.7%), (p <0.0001). Mean age: 36.3±15.3 years, males: 63.1% and 69.4% were Argentine citizens. A 8.9% had been previously treated, 6.1% had co-morbidities. A 70.6% of pulmonary cases was bacteriologically confirmed, 82.8% of them completed the treatment, while 11.5% defaulted. Adverse effects to antituberculosis drugs were observed in 9.5% of cases; male patients showed higher rates of non adherence. G2 had a lower proportion of native people (48.7% vs. 77.1%), (p ≤ 0.0001), higher frequency of co-morbidities (10.7% vs. 4.4%), (p = 0.005), of bacteriologically confirmed pulmonary cases (95% vs. 87%), (p = 0.02) and more adverse effects than G1 (17% vs. 6.6%), (p ≤ 0.0001). In coincidence with other experiences, this work shows high treatment success rates in patients treated under DOT strategy.

Desfechos do retratamento de pacientes com tuberculose com o uso do esquema 3 em Porto Alegre, Brasil / Retreatment of tuberculosis patients in the city of Porto Alegre, Brazil: outcomes

OBJETIVO: Descrever os desfechos do retratamento de pacientes com tuberculose com o uso do esquema 3 (estreptomicina, etambutol, etionamida e pirazinamida por 3 meses + etambutol e etionamida por 9 meses) devido à falência do tratamento com o esquema básico (rifampicina, isoniazida e pirazinamida por 2 meses + rifampicina e isoniazida por 4 meses). MÉTODOS: Estudo descritivo de coorte histórica, não controlada, com adultos que foram tratados com o esquema 3. Foram avaliados os desfechos desse tratamento, as reações adversas aos fármacos, as recidivas e os fatores associados. RESULTADOS: Foram incluídos no estudo 229 pacientes. A taxa de cura geral foi de 62 por cento. Entre os pacientes que usaram a medicação regularmente e aqueles que a usaram irregularmente, a taxa de cura foi de 88 por cento e 31 por cento, respectivamente. Observaram-se reações adversas em 95 pacientes (41,5 por cento), principalmente digestivas. Ocorreram 17 recidivas (12,0 por cento) nos cinco anos de seguimento. CONCLUSIONS: Os desfechos com o uso do esquema 3, em geral, não foram satisfatórios, pois esse esquema foi aplicado em uma população selecionada com alto risco de não adesão ao tratamento e apresenta altas taxas de reações adversas, especialmente as de tipo digestivo, possivelmente causadas pela etionamida. No entanto, para aqueles que conseguiram tomar a medicação regularmente, a taxa de cura foi satisfatória. A taxa de recidiva foi superior àquela preconizada por consensos internacionais, possivelmente devido ao tempo de tratamento curto (apenas 12 meses). Acreditamos que o esquema 3 estendido para 18 meses poderia ser uma alternativa para pacientes com comprovada adesão ao tratamento.

OBJECTIVE: To describe the outcomes of retreatment in tuberculosis patients receiving the regimen known, in Brazil, as regimen 3 (streptomycin, ethambutol, ethionamide, and pyrazinamide for 3 months + ethambutol and ethionamide for 9 months) after treatment failure with the basic regimen (rifampin, isoniazid, and pyrazinamide for 2 months + rifampin and isoniazid for 4 months). METHODS: A descriptive, uncontrolled, historical cohort study involving adult tuberculosis patients treated with regimen 3. We evaluated adverse drug effects, recurrence, treatment outcomes, and associated factors. RESULTS: The study included 229 patients. The overall cure rate was 62 percent. For the patients who used the medications regularly and those who did not, the cure rate was 88 percent and 31 percent, respectively. Adverse events occurred in 95 patients (41.5 percent), and most of those events were related to the gastrointestinal tract. In the five-year follow-up period, relapse occurred in 17 cases (12.0 percent). CONCLUSIONS: Overall, the outcomes of treatment with regimen 3 were unsatisfactory, in part because this regimen was administered to a selected population of patients at high risk for noncompliance with treatment, as well as because it presents high rates of adverse effects, especially those related to the gastrointestinal tract, which might be caused by ethionamide. However, for those who took the medications regularly, the cure rate was satisfactory. The recurrence rate was higher than that recommended in international consensus guidelines, which might be attributable to the short (12-month) treatment period. We believe that regimen 3, extended to 18 months, represents an option for patients with proven treatment compliance.

Avaliação microbiológica do sêmen fresco e congelado de reprodutores caprinos / Microbiological evaluation of buck fresh and frozen semen

Objetivou-se avaliar a flora microbiana no sêmen fresco e congelado de reprodutores caprinos, assim como a eficácia dos antibióticos estreptomicina, penicilina e gentamicina, na viabilidade de doses de sêmen congeladas. Foram utilizados 25 reprodutores de diferentes raças, submetidos a duas colheitas de sêmen através do método da vagina artificial, após higiene da região prepucial. A primeira colheita do sêmen foi realizada visando o exame microbiológico e a segunda teve como objetivo proceder a congelação, após diluição em leite desnatado, utilizando penicilina + estreptomicina (A1), gentamicina(A2) ou sem antibiótico (A3). Ao proceder a avaliação microscópica no sêmen fresco, evidenciou-se média de 87,92 ± 7,76 % de motilidade individual progressiva (MIP) e 4,96 ± 0,20 de vigor espermático. Em relação à avaliação bacteriana, constatou-se principalmente bactérias do gênero Staphylococcus spp e Bacillus sp. Após a congelação do sêmen, não foram evidenciadas diferenças (P>0,05) entre os grupos quantoa MIP e vigor espermático. Entretanto, na avaliação microbiológicapós-descongelação, a bactéria do gênero Staphylococcus spp esteve presente na maioria das amostras. Observou-se também que a gentamicina (13,3mg/mL) apresentou melhor atividade antimicrobianano processo de congelação do sêmen, concluindo-se que pode ser o antibiótico usado na congelação do sêmen de reprodutores caprinos.

The aim of this research was to evaluate the microbial flora in the fresh and frozen semen of goat reproducers, as well as the effectiveness of the antibiotics estreptomicin, penicillin and gentamicin in cryopreservation of semen. It were used 25 males of different breeds, submitted to two semen collect through the artificial vagina method after cleanliness of prepucial region. The first collection of semen aimed the microbiological exam. The second collection had as goal accomplish freezing, after dilution in skimmed milk, with penicillin+ estreptomicin (A1), gentamicin (A2) or control (A3). After microscopic evaluation, it was evidenced average of 87.92 ± 7.76% of MIP and 4.96 ± 0.20 of spermatic vigor in fresh semen. Regarding bacterin evaluation, it was verified, mostly, bacteria of the gender Sthaphylococcus spp and Bacillus sp. After semen cryopreservation, it was observed that there wasn’t difference (P>0.05) among groups in MIP and spermatic vigor. However, in the microbiological evaluationof frozen-thawed semen, bacteria of Sthaphylococcus spp gender was present in great part of samples. Gentamicin (13.3mg/mL) promoted larger inhibition of the bacterial growth in the semen post-freezing, concluding that gentamicin can be the antibiotic used for freezing of goat semen.

Adverse drug reactions observed during DOTS.

A total of 8.37% of the 1195 patients treated at NDTB Centre with DOTS under RNTCP between January 2002 to June 2003 presented with adverse drug reactions. Patients showing any sort of adverse reactions were studied in detail by personal interviews and a semi-structured questionnaire. The profile of patients presenting with adverse reactions showed that majority of the patients (53%) had gastrointestinal reactions, the commonest presenting complaint being nausea and vomiting. General aches and pains were complained by about 35% and giddiness was the presenting complaint in 27% irrespective of the use of streptomycin, although giddiness was observed more often in Category II patients (59%). Skin rash and itching was complained by about 17% of patients and 11% complained of arthralgia, while only 1% had hepatotoxicity during treatment. Majority of the adverse reactions (67%) were observed within the first four weeks of treatment and only 0.25% of patients treated with DOTS had interruption of treatment for short periods.

Comparative Vestibulotoxicity of Different Aminoglycosides in the Guinea Pigs

The histopathological alterations in the vestibule due to aminoglycosides are well defined. Although there are reports comparing the vestibulotoxic effects of the many aminoglycosides, this is the first study to compare the effects of the most commonly used aminoglycosides i.e., streptomycin, gentamicin, amikacin and netilmicin administered both transtympanically and systemically. The transtympanic and systemic administration of each aminoglycoside caused similar histopathological alterations in the vestibule. The most severe degeneration in the cristae ampullaris, utriculus and sacculus was observed after streptomycine administration. The severity of the vestibular damage in terms of magnitude was in the order of streptomycine, gentamicin, amikacin, and netilmicin.

Comparative evaluation of efficacy and safety profile of three anti-tuberculous regimens in Mangalore.

The aim of our study was to evaluate and compare the therapeutic efficacy & safety profile of three different antituberculous regimens for pulmonary tuberculosis. The study sample size included 90 newly diagnosed, sputum positive patients of pulmonary. tuberculosis. 30 each from different groups. The parameters studied were, therapeutic efficacy included weight gain, cough, sputum examination and safety profile: nausea, vomiting, anorexia, gastritis, hepatitis, jaundice diarrhoea, rashes, dizziness, tingling & numbness, flu like symptoms & joint aches. Group-I showed statistically significant weight gain when compared to Group-II. Improvement in cough and conversion to smear negative were seen in 100% of patients in Group-I, 83.3% of patients in Group-II and 93.3% of patients in Group-III. Therapeutic efficacy was highest with Group I regimen, followed by Group III and Group II which was least efficacious. Group II also registered; the maximum cost and highest incidence of adverse effects.

Diagnostic criteria for Tuberculous Meningitis.

OBJECTIVE: Tuberculous Meningitis is associated with a high morbidity and mortality if there is a delay in diagnosis. The diagnosis is based on clinical evaluation since the bacteriological diagnosis takes time and has a low yield. This study attempts to validate these criteria in children with TBM. METHODS: Forty-two children clinically suspected to have TBM were enrolled in the study. History, examination, CT scan and CSF findings were utilized to categorize patients into "definite", "highly probable", "probable" and "possible" TBM based on the criteria laid down by Ahuja et al. The validity of these criteria was tested against bacterial isolation and response to treatment. RESULTS: Thirty one children, with complete data, were included for analysis. Using "improvement on therapy as a criterion for definite TBM, we analyzed the sensitivity and specificity of the Ahuja criteria in diagnosing TBM. Using the criteria of "highly probable" TBM, the sensitivity was 65% with a specificity of 75%. When the criteria of "probable" TBM were used, the sensitivity increased to 96% while the specificity dropped to 38%. In an attempt to make these criteria more appropriate for children, we modified the criteria by including mantoux reaction, and family history of exposure in the criteria. The modified criteria gave a sensitivity of 83% and a specificity of 63%. DISCUSSION: A sensitivity of 65% (highly probable group) implies that 35% of TBM patients will be missed, while the probable criteria gave a 63% false positive rate suggesting that the trade-off for a higher sensitivity makes the criteria very unreliable. Our modification of the criteria gave us a reasonable sensitivity of 83% with a higher specificity of 63%. The false positive rate was also reduced to 38%. Thus the modified Ahuja criteria worked better for children with TBM. CONCLUSION: The modified Ahuja criteria are better applicable for use in pediatric patients with TBM . Since the number of patients was small in this study, the study needs to be validated with a larger sample size.

Genotipificación de mycobacterium tuberculosis y susceptibilidad a drogas / Genetic characterization of mycobacterium tuberculosis and susceptibility to drugs

Conocer la epidemiología de la tuberculosis y transmisión de cepas resistentes en la población estudiada. Estudio prospectivo de cohortes, 150 pacientes sintomáticos respiratorios que acudieron a la consulta de Neumotisiología del Distrito Sanitario Nº3 (n=115) y a la emergencia de Medicina Interna del Hospital Miguel Pérez Carreño (n=35), desde junio de 1995 hasta agosto de 1996. Se tomaron 2 muestras sucesivas de esputo para baciloscopia, cultivo, susceptibilidad a drogas y genotificación por análisis de polimorfismos de longitud de fragmentos de restricción. Se obtuvieron 14 baciloscopias positivas (9,3 por ciento) y 16 cultivos positivos para Mycobacterium tuberculosis, de los cuales 10 fueron baciloscopias positivas y 6 baciloscopias negativas. Se encontró resistencia en 3 cepas: isoniacida (1), estreptomicina (1) y thiocetazona (1), lo que representa una resistencia global del 20 por ciento. El análisis de polimorfismos de longitud de fragmantos de restricción realizado en 14 cepas demostró patrones diferentes. No hay relación epidemiológica entre las cepas aisladas; la resistencia global fue del 20 por ciento y no se encontró multirresistencia

Tuberculosis infantil: experiencia regional en la Araucanía en veinte años / Pediatric tuberculosis: experience at the Araucania region during 20 years

Entre 1979 y 1998 se trataron con diagnóstico de tuberculosis (TBC), 120 pacientes menores de 15 años en el Servicio de Pediatría del Hospital Regional de Temuco. Todos recibieron isoniacida + rifampicina + pirazinamida diariamente por 1 a 2 meses. En TBC meníngea o grave se adicionó estreptomicina como cuarto fármaco antituberculoso. En fase intermitente, generalmente ambulatoria, se empleó isoniacida + rifampicina bimensual por 5 a 7 meses. El diagnóstico de tuberculosis fue bacteriológica en 65 pacientes (54 POR CIENTO), en el resto tuvo fundamentación clínica-epidemiológica. La enfermedad predominó en escolares de origen rural y ascendencia mapuche. En 48 por ciento se obtuvo el antecedente de TBC familiar. En 50 por ciento no se encontró cicatriz BCG. En 70 por ciento hubo compromiso pulmonar exclusivo, en 20 por ciento extrapulmonar solamente y en 10 por ciento asociación. El compromiso del SNC y aparato osteoarticular siguieron en frecuencia al pulmón. Fallecieron 5 pacientes (letalidad 4,1 por ciento). Hubo elevación transitoria de transaminasas en 4,1 por ciento. Se observó recidiva en un paciente. La vacunación BCG, el adecuado manejo de la TBC del adulto y control de los contactos son estrategias fundamentales en la reducción y eliminación de la TBC infantil en Chile.

Velocidad bactericida del suero: propuesta metodológica para precedir la eficacia de la terapia antimicrobiana / Serum bactericidal rate: metodologic proposal to predict the efficacy of antimicrobial therapy

Se propone a la Velocidad Bactericida del Suero (VBS) como una técnica complementaria a la determinación de la "curva de muerte", al poder bactericida del suero (PBS), o a la concentración bactericida mínima (CIM), y que toma de esos métodos las características más ventajosas. Se basa fundamentalmente en cuantificar a distintos tiempos la sobrevida del inóculo bacteriano expuesto al suero del paciente. De esta manera, se evalúa la velocidad de bactericida producida en las primeras horas de contacto con el microorganismo (como en la "curva de muerte") pero a la concentración de droga que ha alcanzado el paciente en estudio (como en el PBS). Algunos ensayos preliminares sugieren que la VBS tendría mayor capacidad para discriminar la respuesta de un agente infeccioso a distintos esquemas terapéuticos que la que tendrían otras determinaciones, si bien se requieren estudios prospectivos para evaluar su valor predictivo.

Resitencia del Bacilo de Koch a drogas antituberculosas mediante laminocultivo y posibles factores que contribuyen a ella

Mediante la técnica de Laminocultivo se realizaron pruebas de sensibilidad en 45 cepas viables de Mycobacterium tuberculosis. Además se evaluó la relación entre la resistencia a las drogas ensayadas y algunos factores epidemiológicos en 35 pacientes provenientes de la provincia de Arequipa a través de la revisión de historias clínicas y visitas domiciliarias. En el presente estudio se encontró que 49 por ciento de cepas presentaron resistencia al menos a un antimicrobiano, 33 por ciento correspondió a multifármacorresistencia. Etambutol presenta la mayor frecuencia en resistencia primaria y en resistencia secundaria Estreptomicina es la más frecuente. Por otra parte el análisis estadístico de los factores epidemiológicos, en el presente estudio, muestra que éstos no contribuyen significativamente en la resistencia del Mycobaterium tuberculosis. Finalmente la técnica utilizada no presentó inconvenientes para su realización

Tratamiento convencional y nuevas drogas para el manejo de la tuberculosis / Conventional treatment and new drugs for tuberculosis management

A pesar de que se cuenta con drogas muy activas contra mycobacterium tuberculosis, la tuberculosis continúa siendo un problema de salud pública. Las malas condiciones de vida y los programas inadecuadas de control han impedido la erradicación de la misma. Los principios fundamentales del tratamiento se basan en un dignóstico racional de la enfermedad, en la vigilancia y seguimiento del plan terapéutico y en el control de respuesta a las drogas y de los efectos secundarios. Actualmente los esquemas se han acortado a 6 meses, con índices derecaídas menores del 15 por ciento e incluyen cuatro drogas de primera línea: estreptomicina, rifampicina, isoniacida y etambutol o pirazinamida durante dos los promeros dos meses y rifampicina +isoniacida por 4 meses. La tuberculosis nunca se trata con una sola droga. El tratamiento debe ser combinado, prolongado y regular. Es importante el manejo de los contactos y enfatizar sobre los aspectos de educación, higiene y buenos hábitos de alimentación

Resistencia inicial del M. tuberculosis a las drogas antituberculosas (1988-1989) / Initial resistance of M. tuberculosis to antituberculous drugs (1988-1989)

Entre 1988-1989, se estudiaron 86 cepas de M. tuberculosis aisladas de esputos de pacientes virgenes al tratamiento y provenientes de las Unidades Departamentales de salud de Lima, Callao y La Libertad. el objetivo fue determinar las cifras de resistencia inicial a drogas antituberculosas en areas del Perú donde las prevalencias de tuberculosis es poco mas del 50 por ciento del total nacional. En promedio se encontro una resistencia inicial para una o mas drogas antituberculosas de 30.2 por ciento. Los porcentajes mas altos de resistencia se encontraron en la provincia del Callao(43.7 por ciento), seguida de Lima (30.3 por ciento) y La Libertad (9.5 por ciento). El analisis de resistencia a una sola droga muestra una RI de 17.4 por ciento para estreptomicina, 3.5 por ciento para isoniacida, 2.3 por ciento para etambutol y 1.2 por ciento para Rifampicina; sin embargo estos porcentages de resistencia aumentan cuando la droga se le considera asociada a otras drogas. Asi, corresponde 22 por ciento a estreptomicina, 9.3 por ciento a isoniacida, 5.8 por ciento a rifampicina. Los resultados demuestran que la resistencia inicial a una o mas drogas es alta en la población estudiada. Se sugiere la necesidad actual de realizar estudios similares a nivel nacional en pacientes con tuberculosis pulmonar